Jordanian firm MS Pharma has entered into an agreement to acquire 100% of the outstanding shares of Greek company Genepharm. The deal is expected to close by the end of April.
Genepharm, a company which develops, manufactures and out-licenses high value, generics, has a strong portfolio alongside an extensive network of 223 customers across 70 countires around the world.
The acquisition expands MS Pharma’s geographic footprint, which at the moment is mainly focused in the Turkey, the Middle East and Africa.
![Het beste uit je content halen met een kloppend verhaal [10 stappen]](https://www.pharmamarketeer.nl/wp-content/uploads/2024/12/businesswoman-working-at-creative-office-2023-11-27-05-24-05-utc-1-80x60.jpg)
